GSK
Important news for Australian women with ovarian cancer will be announced Tuesday 18th January 2022 – with The Therapeutic Goods Administration (TGA) approving a new therapy – called Zejula also known as a PARP inhibitor – as a treatment option for newly diagnosed women with advanced ovarian cancer.
DETAILS:
- 4 Australian women are diagnosed with ovarian cancer every day in Australia, and due to the often late diagnosis and advanced nature of the cancer – 3 of these women will unfortunately die.
- Currently ovarian cancer’s overall 5-year survival rate is almost half that of breast cancer.
- The Therapeutic Goods Administration (TGA) has now approved a new therapy – called Zejula also known as a PARP inhibitor – as a treatment option for newly diagnosed women with advanced ovarian cancer.
- Until now only women with a genetic mutation (BRCA gene – which Angelina Jolie created awareness of) could access this style of treatment.
- This new therapy may be given to women with advanced ovarian cancer regardless of whether they have a genetic mutation – which gives the 75% an new option to consider for their condition.
/Public Release.
